Sorrento Therapeutics Inc., of San Diego, obtained exclusive rights to Cynviloq (Genexol-PM) in Australia, Canada and Mexico from Samyang Biopharmaceuticals, of South Korea. Sorrento already has exclusive rights from Samyang in the U.S. and the 27 European Union countries. Cynviloq is a next-generation branded paclitaxel formulation to treat metastatic breast cancer, non-small-cell lung cancer, pancreatic cancer, and other solid tumors.